Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.58 |
| ▸ | HTR3B | O95264 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | THPO | P40225 | 1/20 | 0.58 |
| ▸ | HTR3A | P46098 | 1/20 | 0.58 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.58 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.58 |
| ▸ | HTR1A | P08908 | 8/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3540666 | 0.95 | ALDH1A1 (0.60) | ALDH1A1HTR3EHTR3BCYP1A2CYP3A4 | |
| SCHEMBL27480804 | 0.93 | ALDH1A1 (0.57) | ALDH1A1HTR3EHTR3BCYP1A2CYP3A4 | |
| SCHEMBL5832121 | 0.88 | ALDH1A1 (0.59) | ALDH1A1HTR3EHTR3BCYP1A2CYP3A4 | |
| SCHEMBL4688608 | 0.86 | ALDH1A1 (0.54) | ALDH1A1HTR3EHTR3BCYP1A2CYP3A4 | |
| SCHEMBL3382640 | 0.83 | ALDH1A1 (0.61) | ALDH1A1HTR3EHTR3BCYP1A2CYP3A4 | |
| SCHEMBL3384126 | 0.83 | ALDH1A1 (0.47) | ALDH1A1HTR3EHTR3BCYP1A2CYP3A4 | |
| SCHEMBL3541348 | 0.81 | ALDH1A1 (0.64) | ALDH1A1HTR3EHTR3BCYP1A2CYP3A4 | |
| SCHEMBL3384612 | 0.80 | HRH3 (0.41) | ALDH1A1HTR3AHTR1A | |
| SCHEMBL3384444 | 0.80 | HRH4 (0.59) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL5873582 | 0.78 | ALDH1A1 (0.76) | ALDH1A1HTR3EHTR3BCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1984366-B1 | 3, 9-DIAZABICYCLO Ý3.3. 1¨NONANE DERIVATIVES AND THEIR USE AS MONOAMINE?NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH AS (DK) | 2010-12-15 | — | — | EP | claimed |
| US-7687517-B2 | 3,9-Diazabicyclo [3.3.1] nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2010-03-30 | — | — | US | claimed |
| US-20080306078-A1 | 3,9-Diazabicyclo [3.3.1] Nonane Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | DANPET AB (SE) | 2008-12-11 | — | — | US | claimed |
| EP-1984366-A1 | 3, 9-DIAZABICYCLO Ý3.3. 1¨NONANE DERIVATIVES AND THEIR USE AS MONOAMINE?NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch A/S (DK) | 2008-10-29 | — | — | EP | claimed |
| WO-2007090887-A1 | 3, 9-DIAZABICYCLO [3.3. 1]NONANE DERIVATIVES AND THEIR USE AS MONOAMINE?NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-08-16 | — | — | WO | claimed |
| EP-1984366-B1 | 3, 9-DIAZABICYCLO Ý3.3. 1¨NONANE DERIVATIVES AND THEIR USE AS MONOAMINE?NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH AS (DK) | 2010-12-15 | — | — | EP | disclosed |
| US-7687517-B2 | 3,9-Diazabicyclo [3.3.1] nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2010-03-30 | — | — | US | disclosed |
| US-20080306078-A1 | 3,9-Diazabicyclo [3.3.1] Nonane Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | DANPET AB (SE) | 2008-12-11 | — | — | US | disclosed |
| EP-1984366-A1 | 3, 9-DIAZABICYCLO Ý3.3. 1¨NONANE DERIVATIVES AND THEIR USE AS MONOAMINE?NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch A/S (DK) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007090887-A1 | 3, 9-DIAZABICYCLO [3.3. 1]NONANE DERIVATIVES AND THEIR USE AS MONOAMINE?NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306078-A1 | 3,9-Diazabicyclo [3.3.1] Nonane Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | SLC18A2, SLC6A2, SLC18A3 | ALDH1A1 608/4885HTR3E 67/4885HTR3B 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.